489 related articles for article (PubMed ID: 36546401)
1. Omicron infection increases IgG binding to spike protein of predecessor variants.
Mahalingam G; Periyasami Y; Arjunan P; Subaschandrabose RK; Mathivanan TV; Mathew RS; Devi RKT; Premkumar PS; Muliyil J; Srivastava A; Moorthy M; Marepally S
J Med Virol; 2023 Feb; 95(2):e28419. PubMed ID: 36546401
[TBL] [Abstract][Full Text] [Related]
2. Ad5-nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants.
Kong W; Zhong Q; Chen M; Yu P; Xu R; Zhang L; Lai C; Deng M; Zhou Q; Xiong S; Liang Y; Wan L; Lin M; Wang M; Mai W; Chen L; Lei Y; Qin N; Zhu J; Ruan J; Huang Q; Kang A; Wang J; Li W; Ji T
J Med Virol; 2023 Jan; 95(1):e28163. PubMed ID: 36127294
[TBL] [Abstract][Full Text] [Related]
3. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
[TBL] [Abstract][Full Text] [Related]
4. Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection.
Goto T; Chong Y; Tani N; Susai N; Yoshinaga T; Sasaki T; Taniguchi M; Kusakabe T; Shimono N; Akashi K; Ikematsu H
Vaccine; 2023 Nov; 41(47):7019-7025. PubMed ID: 37858449
[TBL] [Abstract][Full Text] [Related]
5. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
[TBL] [Abstract][Full Text] [Related]
7. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
Elife; 2022 Aug; 11():. PubMed ID: 36004719
[TBL] [Abstract][Full Text] [Related]
8. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
[TBL] [Abstract][Full Text] [Related]
9. Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron.
Zhu KL; Gao HX; Yao L; Rong J; Yang L; Zhang Z; Jiang P; Duan LJ; Wang GL; Dai EH; Ma MJ
J Infect Dis; 2022 Nov; 226(9):1551-1555. PubMed ID: 35429398
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of Different Classes and Subclasses of Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants after Coronavirus Disease 2019 and CoronaVac Vaccination in Thailand.
Poolchanuan P; Matsee W; Sengyee S; Siripoon T; Dulsuk A; Phunpang R; Pisutsan P; Piyaphanee W; Luvira V; Chantratita N
mSphere; 2023 Feb; 8(1):e0046522. PubMed ID: 36688637
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with BNT162b2 and ChAdOx1 nCoV-19 Induces Cross-Reactive Anti-RBD IgG against SARS-CoV-2 Variants including Omicron.
Gerges D; Kapps S; Hernández-Carralero E; Freire R; Aiad M; Schmidt S; Winnicki W; Reiter T; Pajenda S; Schmidt A; Sunder-Plassmann G; Wagner L
Viruses; 2022 May; 14(6):. PubMed ID: 35746653
[TBL] [Abstract][Full Text] [Related]
13. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
14. Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants.
Chang MR; Ke H; Coherd CD; Wang Y; Mashima K; Kastrunes GM; Huang CY; Marasco WA
EBioMedicine; 2022 Jun; 80():104025. PubMed ID: 35533497
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 vaccine breakthrough infections (VBI) by Omicron variant (B.1.1.529) and consequences in structural and functional impact.
Abduljaleel Z; Melebari S; Athar M; Dehlawi S; Udhaya Kumar S; Aziz SA; Dannoun AI; Malik SM; Thasleem J; George Priya Doss C
Cell Signal; 2023 Sep; 109():110798. PubMed ID: 37423342
[TBL] [Abstract][Full Text] [Related]
16. Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern.
McNamara RP; Maron JS; Boucau J; Roy V; Webb NE; Bertera HL; Barczak AK; Positives Study Staff T; Franko N; Logue JK; Kemp M; Li JZ; Zhou L; Hsieh CL; McLellan JS; Siedner MJ; Seaman MS; Lemieux JE; Chu HY; Alter G
mBio; 2023 Aug; 14(4):e0090223. PubMed ID: 37535402
[TBL] [Abstract][Full Text] [Related]
17. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
[TBL] [Abstract][Full Text] [Related]
18. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.
Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K
Front Immunol; 2022; 13():946318. PubMed ID: 35928813
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.
Servellita V; Syed AM; Morris MK; Brazer N; Saldhi P; Garcia-Knight M; Sreekumar B; Khalid MM; Ciling A; Chen PY; Kumar GR; Gliwa AS; Nguyen J; Sotomayor-Gonzalez A; Zhang Y; Frias E; Prostko J; Hackett J; Andino R; Wadford DA; Hanson C; Doudna J; Ott M; Chiu CY
Cell; 2022 Apr; 185(9):1539-1548.e5. PubMed ID: 35429436
[TBL] [Abstract][Full Text] [Related]
20. Humoral Response Kinetics and Cross-Immunity in Hospitalized Patients with SARS-CoV-2 WT, Delta, or Omicron Infections: A Comparison between Vaccinated and Unvaccinated Cohorts.
Kang H; Lee J; Jung J; Oh EJ
Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
